Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454298 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00454298 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 2 participants.
The verdict
NCT00454298, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The main purpose of the study is to find out if, after 4 weeks of dosing, signs of the investigational drug AGG-523, or its effects, can be measured in urine, blood, or the knee joint. A secondary purpose is to evaluate the safety of taking the drug either once a day or twice a day for 4 weeks.
Interventions
- DRUG AGG-523 (Aggrecanase Inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00454298
The ClinicalTrials.gov registry entry for NCT00454298 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AGG-523 (Aggrecanase Inhibitor) is the first listed.
NCT00454298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00454298 about?
NCT00454298 is a clinical study titled "Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement". The main purpose of the study is to find out if, after 4 weeks of dosing, signs of the investigational drug AGG-523, or its effects, can be measured in urine, blood, or the knee joint. A secondary purpose is to evaluate the safety of taking the drug either once a day or twice a day for 4 weeks.
What is the current status of trial NCT00454298?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2007-05. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00454298?
The interventions under investigation include: AGG-523 (Aggrecanase Inhibitor) (DRUG).
Who is sponsoring clinical trial NCT00454298?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.